GrayBella Capital

ATAI Life Sciences AG is a biotechnology company based in Munich, Germany, with additional offices in Berlin and London. Founded in 2018, the company focuses on developing innovative therapies for mental health disorders, including depression, anxiety, and substance use disorders. ATAI utilizes psychedelic compounds and other therapeutic methods to address these conditions, collaborating with various partners and research institutions to enhance its drug development pipeline. Its clinical-stage product portfolio features therapies such as COMP360 (Psilocybin therapy), PCN-101 (R-ketamine), and others derived from compounds like MDMA and ibogaine. By working with experts in the field, ATAI aims to ensure the efficacy and safety of its treatments. The company has garnered recognition for its contributions to mental health research and has secured partnerships and funding to further its initiatives in transforming mental health care.

CN Bio Innovations Ltd, established in 2008 and headquartered in Cambridge, UK, specializes in developing and providing Organ-on-Chip devices to pharmaceutical and biotech companies. These devices enable more accurate preclinical drug testing by replicating human organ functions in vitro. CN Bio's offerings include microphysiological systems and consumables, used to analyze novel compounds, assess toxicity and safety, and support research scientists in various fields such as oncology, infectious diseases, metabolism, and inflammation. The company's flagship product, the LiverChip platform, features a full viral lifecycle model of hepatitis B, currently employed in drug discovery collaborations with leading pharmaceutical and biotech companies. CN Bio's work is backed by prestigious grants and partnerships with academic institutions, aiming to accelerate the development of breakthrough therapies for serious human diseases.

Omnio Group, founded in 2018 and headquartered in London, is a provider of banking-as-a-Service solutions designed for banks, building societies, credit unions, and various corporate clients. The company specializes in digital banking, managed services, and digital payment solutions, enabling its clients to offer innovative and reliable financial services. Omnio's platform incorporates features such as loyalty programs and back-office services, allowing clients to enhance their product offerings and generate new revenue streams through embedded financial services. With a presence in Europe, Australia, North America, and Africa, Omnio supports over 130 small financial institutions and collaborates with leading businesses and government organizations to deliver effective financial products tailored to meet evolving customer needs.